Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Tuebingen, Germany and Houston, Texas – 8 July 2019 – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).
Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer (CSO) of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.
Peter Chambré, Chairman of Immatics, says: “The Board is delighted to appoint Harpreet as CEO to lead Immatics in the next phase of its development, as the Company progresses its pipeline of immunotherapy candidates. Harpreet is an exceptional organizational leader and scientist and over the past three years has led the building of the Immatics US organization and creation of Immatics’ clinical pipeline and capabilities in adoptive cellular therapy, as well as guiding the Company’s overall scientific development since its early days. We are very excited about the prospects and opportunities for Immatics, with Harpreet as CEO.”
Harpreet Singh comments: “I am thrilled to be chosen as CEO of Immatics. We hold the key to unlock the power of cancer immunotherapies in solid cancers. Built on world-leading target and TCR discovery platforms we are developing powerful pipelines of novel adoptive cellular as well as bispecific therapy products - on our own, as well as with world-class partners. The opportunity to lead this exceptional company and its outstanding people that are passionately dedicated to delivering the power of T cells to cancer patients, is a true privilege.”
Notes To Editors
About Immatics
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The Company’s transformative product candidates are ‒ best in class ‒ Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT® technology. XPRESIDENT® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer and any HLA type. Together with Immatics’ powerful TCR discovery technology XCEPTOR®, these two platforms allow a full range of cancer therapies to be developed.
Immatics’ pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine® and ACTallo®approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules.
Operating from Tuebingen, Munich (Germany) and Houston (Texas), the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics’ mission to deliver the power of T cells to cancer patients.
About Harpreet Singh, Ph.D.
Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.
Since the foundation, he has served as Managing Director and Chief Scientific Officer, helping to grow the Company from a start-up to a leading biotech player in the field of immuno-oncology. Harpreet has played a leadership role in raising more than US$200m of venture capital funding over several financing rounds. In 2015, Harpreet became President & CEO of Immatics US, overseeing all operations of Immatics in Houston, Texas to develop next-generation Adoptive Cell Therapies (ACT). He led the team that achieved a $20m CPRIT grant by the State of Texas. Harpreet was awarded “Private Company CEO of the Year” at the Lifestars Awards 2018 (in association with Jefferies), in recognition of his achievements. In 2019, Harpreet became CEO of Immatics Biotechnologies.
Harpreet is the inventor on numerous granted patents and patent applications and co-author of numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Lancet Oncology. A scholar of Prof. Hans-Georg Rammensee, Harpreet completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.
For regular updates about Immatics, visit www.immatics.com and follow us on Twitter and LinkedIn.
Issued for and on behalf of Immatics by Instinctif Partners.
For more information please contact:
Immatics Biotechnologies GmbH
Anja Heuer, Corporate Communications Manager
T: +49 89 540415-606
E: media@immatics.com
Instinctif Partners
Sue Charles / Genevieve Wilson
T: +44 20 7457 2859
E: Immatics@instinctif.com
